In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine

在ACHIEVE-4研究中，服用Foundayo的参与者发生MACE-4的风险降低了16%，发生MACE-3的风险降低了23%，达到了相较于甘精胰岛素非劣效性的主要目标。

In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57% lower risk of all-cause death vs. insulin glargine, suggesting the potential for more comprehensive health benefits

在预先计划的分析中，与甘精胰岛素相比，Foundayo 使心血管死亡风险降低 53%，全因死亡风险降低 57%，这表明其具有提供更全面健康获益的潜力。

INDIANAPOLIS

印第安纳波利斯

,

，

Sept. 30, 2026

2026年9月30日

/PRNewswire/ -- Eli Lilly and Company (NYSE:

/美通社/ -- 礼来公司（纽约证券交易所：

LLY

礼来

), the maker of Zepbound (tirzepatide), today announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. In the trial, which is the largest and longest study of this medicine in type 2 diabetes to date, Foundayo demonstrated a non-inferior risk of major adverse cardiovascular events (MACE) and improved A1C, weight and other key measures of cardiometabolic health compared with insulin glargine.

Zepbound（替尔泊肽）的制造商今日公布了评估Foundayo（orforglipron）与滴定胰岛素甘精在心血管风险增加的2型糖尿病且伴有肥胖或超重的成人中的疗效和安全性的3期ACHIEVE-4试验的详细结果。在该试验中，这是迄今为止针对该药物在2型糖尿病中规模最大、持续时间最长的研究，Foundayo显示出与胰岛素甘精相比，主要不良心血管事件（MACE）的风险非劣效，并且在A1C、体重以及其他关键的心代谢健康指标方面有所改善。

Results from the trial were presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, and simultaneously published in .

试验结果在意大利米兰举行的欧洲糖尿病研究协会（EASD）第62届年会上公布，并同步发表于。

The Lancet

柳叶刀

.

。

'For people living with type 2 diabetes, protecting the heart is as important as controlling blood sugar,' said Klara Klein, M.D., Ph.D., Assistant Professor of Medicine, University of North Carolina School of Medicine. 'ACHIEVE-4 reaffirmed the safety of orforglipron and demonstrated an association with a lower risk of major cardiovascular events and death.

“对于2型糖尿病患者而言，保护心脏与控制血糖同样重要，”北卡罗来纳大学医学院医学助理教授Klara Klein医学博士、哲学博士表示。“ACHIEVE-4研究再次证实了orforglipron的安全性，并表明其与主要心血管事件和死亡风险降低相关。”

These results, paired with the simple administration of a once-daily pill, taken without fasting or water restrictions, could make orforglipron a compelling potential option across the globe.'.

这些结果，加上每日一次、无需禁食或限制饮水的简便给药方式，可能使orforglipron成为全球范围内一个极具吸引力的潜在选择。

In the trial, the risk of cardiovascular death, heart attack, stroke, or hospitalization for unstable sudden chest pain (MACE-4) was 16% lower for Foundayo vs. insulin glargine (hazard ratio: 0.84; 95.0% CI: 0.59 to 1.20), meeting the prespecified criteria for demonstrating non-inferiority (upper limit of 95.0% CI of the hazard ratio < 1.8)..

在试验中，与甘精胰岛素相比，Foundayo 将心血管死亡、心肌梗死、卒中或因不稳定性突发胸痛住院（MACE-4）的风险降低了 16%（风险比：0.84；95.0% 置信区间：0.59 至 1.20），达到了预先设定的非劣效性判定标准（风险比的 95.0% 置信区间上限 < 1.8）。

1

1

The risk of cardiovascular death, heart attack, or stroke (MACE-3) was 23% lower for Foundayo vs. insulin glargine (hazard ratio: 0.77; 95.0% CI: 0.52 to 1.13). In pre-planned analyses, the risk of cardiovascular death was 53% lower (hazard ratio: 0.47; 95.0% CI: 0.25 to 0.90) and the risk of all-cause death was 57% lower (hazard ratio: 0.43; 95.0% CI: 0.25 to 0.75) for Foundayo vs.

与甘精胰岛素相比，Foundayo使心血管死亡、心肌梗死或卒中（MACE-3）的风险降低了23%（风险比：0.77；95.0%置信区间：0.52至1.13）。在预先计划的分析中，与甘精胰岛素相比，Foundayo使心血管死亡风险降低了53%（风险比：0.47；95.0%置信区间：0.25至0.90），全因死亡风险降低了57%（风险比：0.43；95.0%置信区间：0.25至0.75）。

insulin glargine..

甘精胰岛素

2

2

In addition to demonstrating cardiovascular safety, Foundayo was associated with meaningful improvements across multiple cardiovascular risk factors. At week 52, participants treated with Foundayo experienced reductions in waist circumference by 7.0 cm, systolic blood pressure by 4.4 mmHg, triglycerides by 18.9%, non-HDL cholesterol by 6.6% and hsCRP, a marker of inflammation, by 38.9%..

除了证明心血管安全性外，Foundayo还与多种心血管风险因素的显著改善相关。在第52周时，接受Foundayo治疗的参与者腰围减少了7.0厘米，收缩压降低了4.4毫米汞柱，甘油三酯下降了18.9%，非高密度脂蛋白胆固醇下降了6.6%，炎症标志物超敏C反应蛋白（hsCRP）下降了38.9%。

2

2

Foundayo was also associated with a slower decline in kidney function, a key contributor to cardiovascular risk, including a 2.8 mL/min/1.73 m² smaller reduction in eGFR and a 27.1% greater reduction in albuminuria compared to insulin glargine.

与甘精胰岛素相比，Foundayo 还与肾功能下降速度较慢相关，这是心血管风险的一个关键影响因素；具体表现为估算肾小球滤过率（eGFR）的降幅减少 2.8 mL/min/1.73 m²，尿白蛋白排泄量的降幅增加 27.1%。

2

2

ACHIEVE-4 Detailed Results

ACHIEVE-4 详细结果

Foundayo

Foundayo

Insulin Glargine

甘精胰岛素

Primary Endpoint

主要终点

Time to first occurrence of

首次发生时间

MACE-4

MACE-4

i

我

Hazard ratio = 0.84

风险比 = 0.84

95.0% CI: 0.59 to 1.20

95.0% 置信区间：0.59 至 1.20

ii

ii

p = 0.336

p = 0.336

Key Secondary Endpoints

关键次要终点

Time to first occurrence of

首次发生时间

MACE-3

MACE-3

i

我

Hazard ratio = 0.77

风险比 = 0.77

95.0% CI: 0.52 to 1.13

95.0% 置信区间：0.52 至 1.13

p = 0.181

p = 0.181

Change in A1C from

糖化血红蛋白（A1C）的变化

mean baseline of

的均值基线

8.22% at 52 Weeks

52周涨幅8.22%

iii

三

-1.6 %

-1.6%

-1.0 %

-1.0%

Estimated treatment difference:

估计治疗差异：

-0.66 (95.0% CI: -0.74 to -0.58)

-0.66（95.0% 置信区间：-0.74 至 -0.58）

p <0.001

p < 0.001

Change in body

身体变化

weight from mean

距均值的权重

baseline of 90.9 kg

基线体重为 90.9 公斤

(200.4 lbs; BMI of 32.6 kg/m²) at 52 Weeks

（200.4 磅；BMI 为 32.6 kg/m²）在第 52 周

iii

三

-8.8%

-8.8%

(-8.1 kg / -17.9 lbs)

(-8.1 公斤 / -17.9 磅)

+1.7%

+1.7%

(+1.4 kg / +3.1 lbs)

（+1.4 千克 / +3.1 磅）

Estimated treatment difference:

估计治疗差异：

-10.42% (95.0% CI: -10.92 to -9.93)

-10.42%（95.0% 置信区间：-10.92 至 -9.93）

p < 0.001

p < 0.001

Secondary Endpoints at 104 Weeks

104周时的次要终点

Percent of participants achieving A1C ≤6.5%

达到糖化血红蛋白（A1C）≤6.5%的参与者百分比

iii, iv

iii，iv

54.6 %

54.6%

23.8 %

23.8%

Percent of participants achieving body weight reduction of ≥10%

体重减轻≥10%的参与者百分比

iii, iv

iii，iv

35.9 %

35.9%

3.4 %

3.4%

Additional Pre-Planned Analysis

额外预计划分析

All-cause death

全因死亡

i,iv

我，四

Hazard ratio = 0.43

风险比 = 0.43

95.0% CI: 0.25 to 0.75

95.0% 置信区间：0.25 至 0.75

p = 0.002

p = 0.002

Cardiovascular death

心血管死亡

i,iv

我，四

Hazard ratio = 0.47

风险比 = 0.47

95.0% CI: 0.25 to 0.90

95.0% 置信区间：0.25 至 0.90

p = 0.019

p = 0.019

i

我

Time to first event analysis using Cox proportional hazard model for CI and log-rank for p-value. All data from randomization to end of the study were included in the analysis.

采用Cox比例风险模型分析至首次事件发生的时间，并使用对数秩检验计算p值。分析纳入了从随机化至研究结束的所有数据。

ii

ii

Non-inferiority (upper limit of 95% CI of the hazard ratio < 1.8).

非劣效性（风险比的95%置信区间上限<1.8）。

iii

三

Results of A1C and body weight were based on efficacy estimand.

糖化血红蛋白（A1C）和体重的结果基于疗效估计量。

3

3

iv

四

Not controlled for family-wise type 1 error.

未对族系第一类错误进行控制。

'Foundayo has consistently delivered strong efficacy in type 2 diabetes across our Phase 3 ACHIEVE program,' said Thomas Seck, M.D., senior vice president of product development, Lilly Cardiometabolic Health. 'In ACHIEVE-4, our largest and longest study of this medicine, Foundayo helped more than half of participants reach an A1C of 6.5% or lower, with durable reductions in A1C and body weight and a favorable overall safety profile.

“在我们的III期ACHIEVE项目中，Foundayo在2型糖尿病治疗中始终展现出强劲的疗效，”礼来心血管代谢健康事业部产品开发高级副总裁Thomas Seck医学博士表示。“在ACHIEVE-4研究中——这是本品规模最大、持续时间最长的研究——Foundayo帮助超过半数的受试者将糖化血红蛋白（A1C）降至6.5%或更低，并且实现了持久的A1C和体重降低，整体安全性良好。”

This kind of efficacy reinforces our confidence that Foundayo could change how physicians and patients approach the treatment of type 2 diabetes.'.

这种疗效进一步增强了我们的信心，即Foundayo有望改变医生和患者对2型糖尿病治疗的方式。

The overall safety and tolerability profile of Foundayo in ACHIEVE-4 was generally consistent with previous trials and with other incretins. The most common adverse events for participants taking Foundayo were nausea, vomiting, diarrhea, decreased appetite, and constipation. During the 52-week minimum treatment period, 10.6% of participants taking Foundayo discontinued treatment due to adverse events..

在 ACHIEVE-4 研究中，Foundayo 的总体安全性和耐受性特征与既往试验及其他肠促胰素类药物基本一致。接受 Foundayo 治疗的参与者中最常见的不良事件为恶心、呕吐、腹泻、食欲减退和便秘。在至少 52 周的治疗期间，10.6% 的 Foundayo 治疗参与者因不良事件而中止治疗。

To further evaluate the impact Foundayo has on cardiovascular outcomes in adults with obesity or overweight with or without type 2 diabetes, Lilly is conducting ATTAIN-OUTCOMES, an ongoing Phase 3 study in adults with established cardiovascular or kidney disease.

为了进一步评估Foundayo对患有肥胖或超重（伴或不伴2型糖尿病）的成年人心血管结局的影响，礼来公司正在开展ATTAIN-OUTCOMES研究，这是一项针对已确诊心血管疾病或肾脏疾病的成年人的正在进行中的III期临床试验。

About Foundayo (orforglipron)

关于 Foundayo（orforglipron）

Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day with no planning around food or drink..

Foundayo™（orforglipron）已获美国食品药品监督管理局（FDA）批准，用于肥胖成人，或伴有体重相关医学问题的超重成人，在减少热量饮食和增加体力活动的基础上，减少多余体重并长期维持减重效果。Foundayo 是一种每日一次的小分子（非肽类）口服胰高血糖素样肽-1受体激动剂，可在一天中的任何时间服用，无需围绕饮食进行规划。

Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence..

Orforglipron 由中外制药株式会社发现，并于 2018 年由礼来公司获得许可。除了用于慢性体重管理外，orforglipron 正在被研究作为治疗 2 型糖尿病、阻塞性睡眠呼吸暂停、膝骨关节炎疼痛、高血压、外周动脉疾病和压力性尿失禁的潜在药物。

About ACHIEVE-4 and ACHIEVE clinical trial program

关于 ACHIEVE-4 和 ACHIEVE 临床试验项目

ACHIEVE-4 (NCT05803421) is a Phase 3, event-driven, randomized, open-label trial evaluating the efficacy and safety of Foundayo compared with insulin glargine U-100 in adults with type 2 diabetes and obesity or overweight (BMI ≥25 kg/m

ACHIEVE-4（NCT05803421）是一项III期、以事件为驱动、随机、开放标签的临床试验，旨在评估Foundayo与甘精胰岛素U-100相比，在患有2型糖尿病且肥胖或超重（BMI ≥25 kg/m²）的成人患者中的疗效和安全性。

2

2

) with increased risk of cardiovascular events. The trial randomized 2,749 participants across the U.S., Argentina, Austria, Brazil, Czechia, Germany, Greece, India, Italy, Mexico, Puerto Rico, Romania, Slovakia, South Korea, Spain and Turkey to receive either escalating doses of Foundayo or insulin glargine.

）心血管事件风险增加。该试验在美国、阿根廷、奥地利、巴西、捷克、德国、希腊、印度、意大利、墨西哥、波多黎各、罗马尼亚、斯洛伐克、韩国、西班牙和土耳其将2,749名参与者随机分配，接受递增剂量的Foundayo或甘精胰岛素治疗。

The primary objective of the study was to demonstrate that Foundayo was non-inferior in the risk of major adverse cardiovascular events (MACE-4) compared to insulin glargine in adults with type 2 diabetes and obesity or overweight with increased risk for cardiovascular events who have taken at least one and no more than three oral anti-diabetic medications for at least 90 days prior to study start.

本研究的主要目的是证明，在患有2型糖尿病且肥胖或超重、心血管事件风险增加，并在研究开始前至少90天内服用过至少一种但不超过三种口服降糖药物的成人中，Foundayo在主要不良心血管事件（MACE-4）风险方面不劣于甘精胰岛素。

Study participants had an A1C between ≥7.0% and ≤10.5% (≥7.5% and ≤10.5% if background diabetes medication included a sulfonylurea) and a BMI of ≥25 kg/m.

研究参与者的糖化血红蛋白（A1C）水平在 ≥7.0% 至 ≤10.5% 之间（如果背景糖尿病药物包含磺脲类药物，则为 ≥7.5% 至 ≤10.5%），且体重指数（BMI）≥25 kg/m²。

2

2

with stable weight (±5%) for at least 90 days prior to study start. Participants randomized to Foundayo initiated treatment with 0.8 mg once daily and increased the dose every four weeks until reaching a maximum tolerated dose (up to 17.2 mg). The trial was conducted using an investigational formulation of Foundayo at dosages equivalent to Foundayo tablets..

在研究开始前至少90天内体重稳定（波动范围为±5%）。随机分配至Foundayo组的参与者以0.8 mg的剂量每日一次开始治疗，并每四周增加一次剂量，直至达到最大耐受剂量（最高17.2 mg）。本试验采用与Foundayo片剂等效剂量的Foundayo研究用制剂进行。

The ACHIEVE Phase 3 global clinical development program for Foundayo began in 2023 and enrolled more than 6,000 people with type 2 diabetes across five global registration trials.

Foundayo 的 ACHIEVE 三期全球临床开发计划于 2023 年启动，在五项全球注册试验中招募了超过 6,000 名 2 型糖尿病患者。

Endnotes

尾注

Time to first event analysis using Cox proportional hazard model using all randomized participants exposed to ≥1 dose of study intervention.

采用Cox比例风险模型对所有随机化且接受≥1剂研究干预的参与者进行首次事件时间分析。

All-cause death, waist circumference, serum lipids, blood pressure, hsCRP, cardiovascular death and kidney function endpoints were not controlled for family-wise type 1 error. Waist circumference, eGFR, albuminuria, serum lipids, blood pressure and hsCRP were based on efficacy estimand.

全因死亡、腰围、血清脂质、血压、高敏C反应蛋白（hsCRP）、心血管死亡和肾功能终点未对家族-wise I类错误进行控制。腰围、估算肾小球滤过率（eGFR）、白蛋白尿、血清脂质、血压和高敏C反应蛋白（hsCRP）基于疗效 estimand。

The efficacy estimand represents efficacy had all randomized participants remained on study intervention (with possible dose interruptions and/or dose modifications) without initiating additional antihyperglycemic medications (>14 days of use).

疗效估计量代表所有随机化参与者在未启动额外降糖药物（使用超过14天）的情况下，持续接受研究干预（可能包括剂量中断和/或剂量调整）的疗效。

U.S. FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS

美国 FOUNDAYO 适应症与安全摘要（含警告）

Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Foundayo（发音：fown-DAY-oh）是一种处方药，配合低热量饮食和增加体力活动，用于帮助肥胖成人，或伴有体重相关医学问题的部分超重成人，减轻多余体重并维持减重效果。

Foundayo should not be used with other

Foundayo 不应与其他

GLP-1

GLP-1

receptor agonist medicines.

受体激动剂药物。

It is not known if Foundayo is safe and effective for use in children.

尚不清楚 Foundayo 在儿童中使用的安全性和有效性。

Warnings –

警告 –

Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Foundayo 可能导致甲状腺肿瘤，包括甲状腺癌。请留意可能的症状，如颈部肿块或肿胀、声音嘶哑、吞咽困难或呼吸短促。如果出现任何上述症状，请告知您的医疗保健提供者。

Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).

如果您或您的任何家庭成员曾患有称为髓样甲状腺癌（MTC）的甲状腺癌，请勿使用 Foundayo。

Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

如果您患有多发性内分泌腺瘤病2型（MEN 2），请勿使用Foundayo。

Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

如果您曾对奥福格列酮（orforglipron）或 Foundayo 的任何成分发生过严重过敏反应，请勿使用 Foundayo。

Foundayo

Foundayo

may cause serious side effects, including:

可能导致严重的副作用，包括：

Inflammation of

炎症

the pancreas

胰腺

(pancreatitis).

（胰腺炎）。

Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

如果您出现持续不缓解的严重腹痛（腹部疼痛），无论是否伴有恶心或呕吐，请立即停用 Foundayo 并马上联系您的医疗保健提供者。有时，您可能会感到腹痛放射至背部。

Severe stomach problems.

严重的胃部问题。

Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

使用 Foundayo 的患者中曾有胃部问题（有时严重）的报告。如果您出现严重或持续不缓解的胃部问题，请告知您的医疗保健提供者。

Dehydration

脱水

leading

领先

to kidney problems.

导致肾脏问题。

Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

腹泻、恶心和呕吐可能导致体液流失（脱水），从而引发肾脏问题。补充水分对于降低脱水风险至关重要。如果出现持续不退的恶心、呕吐或腹泻，请立即告知您的医疗保健提供者。

Low blood sugar (hypoglycemia).

低血糖（低血糖症）。

Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea.

如果您将 Foundayo 与可能导致低血糖的药物（如胰岛素或磺酰脲类药物）联合使用，您发生低血糖的风险可能会更高。

Signs and symptoms of low blood sugar may include

低血糖的体征和症状可能包括

dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

头晕或头昏、出汗、意识模糊或嗜睡、头痛、视力模糊、言语不清、颤抖、心跳加快、焦虑、易怒、情绪变化、饥饿感、虚弱或感到坐立不安。

Serious allergic reactions.

严重过敏反应。

Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

如果出现严重过敏反应的任何症状，包括面部、嘴唇、舌头或喉咙肿胀，呼吸或吞咽困难，严重皮疹或瘙痒，昏厥或感到头晕，或心跳极快，请立即停止使用 Foundayo 并寻求医疗帮助。

Changes in vision in patients with type 2 diabetes.

2型糖尿病患者的视力变化。

Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

如果在接受 Foundayo 治疗期间出现视力变化，请告知您的医疗保健提供者。

Gallbladder problems.

胆囊问题。

Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

部分使用 Foundayo 的患者出现了胆囊问题。如果您出现胆囊问题的症状，包括上腹部疼痛、发热、皮肤或眼睛发黄（黄疸）或陶土色粪便，请立即告知您的医疗保健提供者。

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).

在手术或其他使用麻醉或深度镇静（深度睡眠状态）的操作过程中，食物或液体进入肺部。

Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

服用 Foundayo 可能会增加在手术或其他操作过程中食物进入肺部的风险。在计划进行手术或其他操作之前，请告知您的医疗保健提供者您正在服用 Foundayo。

Common side effects

常见副作用

The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away. .

Foundayo 最常见的副作用包括恶心、便秘、腹泻、呕吐、消化不良、胃痛（腹痛）、头痛、腹部肿胀、疲劳感、嗳气、胃灼热、胀气和脱发。这些并非 Foundayo 所有可能的副作用。如有任何困扰您或持续不退的副作用，请咨询您的医疗保健提供者。

Tell your doctor if you have any side effects.

如果您出现任何副作用，请告知您的医生。

You can report side effects at 1-800-FDA-1088 or

您可以通过 1-800-FDA-1088 报告副作用，或

www.fda.gov/medwatch

www.fda.gov/medwatch

.

。

Before taking

在服用之前

Foundayo

Foundayo

Tell your healthcare provider about all the medicines you take.

请告知您的医疗保健提供者您正在服用的所有药物。

Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works.

Foundayo 可能会影响某些药物的作用方式，而某些药物也可能会影响 Foundayo 的作用方式。

Pregnancy Exposure Registry

妊娠暴露登记处

: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). .

将设立一个妊娠暴露登记系统，用于记录在妊娠期间服用 Foundayo 的女性。该登记系统的目的是收集有关您和您宝宝健康状况的信息。请与您的医疗保健提供者讨论如何参与该登记系统，或您可以联系礼来公司（Eli Lilly and Company），电话：1-800-LillyRx（1-800-545-5979）。

If you take birth control pills by mouth, talk to your healthcare provider before you take

如果您口服避孕药，请在服用前咨询您的医疗保健提供者

Foundayo. Birth control pills may not work as well while taking

Foundayo。在服用期间，避孕药的效果可能会降低。

Foundayo.

Foundayo。

Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo.

您的医疗保健提供者可能会建议您在开始使用 Foundayo 后的 30 天内，以及每次增加 Foundayo 剂量后的 30 天内，采用另一种类型的避孕措施。

Talk to your healthcare provider about low blood sugar and how to manage it.

与您的医疗保健提供者讨论低血糖问题及其管理方法。

Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.

如果您正在服用治疗糖尿病的药物，包括胰岛素或磺酰脲类药物，请告知您的医疗保健提供者。

Review these questions with your healthcare provider:

与您的医疗保健提供者一起审阅以下问题：

❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?

❑ 您是否有其他疾病，包括胰腺或肾脏问题，或严重的肝脏问题、严重的胃部问题（如胃排空延迟[胃轻瘫]或食物消化障碍）？

❑ Do you have a history of diabetic retinopathy?

❑ 您是否有糖尿病视网膜病变病史？

❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?

❑ 您是否已安排进行需要使用麻醉或深度镇静（深睡状态）的手术或其他操作？

❑ Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.

❑ 您是否怀孕或计划怀孕？Foundayo 可能对您的胎儿造成伤害。

❑ Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.

❑ 您是否正在哺乳或计划哺乳？在 Foundayo 治疗期间，不建议进行母乳喂养。

❑ Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

❑ 您是否正在服用其他处方药、非处方药、维生素或草本补充剂？

How to take

服用方法

Take Foundayo exactly as your healthcare provider tells you to.

请严格按照您的医疗保健提供者的指示服用 Foundayo。

Use Foundayo with a reduced-calorie diet and increased physical activity.

配合低热量饮食和增加体力活动使用 Foundayo。

Take Foundayo by mouth 1 time each day, with or without food.

每日口服一次 Foundayo，可与食物同服或空腹服用。

Swallow tablets whole. Do not break, crush, or chew the tablet.

整片吞服。请勿掰开、压碎或咀嚼药片。

If you miss a dose, take it as soon as possible.

如果漏服一剂，请尽快补服。

Do not

不要

take

拿

2

2

doses of Foundayo in the same day.

同日服用 Foundayo 的剂量。

Do not take more than 1 tablet per day.

每日服用不得超过1片。

If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment.

如果您连续7天或更长时间漏服Foundayo，请联系您的医疗保健提供者，讨论如何重新开始治疗。

If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

如果您服用了过量的 Foundayo，请立即联系您的医疗保健提供者，或拨打中毒帮助热线 1-800-222-1222，或前往最近的医院急诊室。

Learn more

了解更多

Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to

Foundayo 是一种处方药，有 0.8 mg、2.5 mg、5.5 mg、9 mg、14.5 mg 或 17.2 mg 的口服片剂。如需更多信息，请致电 1-800-545-5979 或访问

foundayo.lilly.com

foundayo.lilly.com

.

。

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it.

本摘要提供关于 Foundayo 的基本信息，但并未涵盖该药品的所有已知信息。每次配药时，请阅读随处方附带的信息。本信息不能替代与医生的沟通。请务必就 Foundayo 及其服用方法咨询您的医生或其他医疗保健提供者。

Your doctor is the best person to help you decide if Foundayo is right for you..

您的医生是帮助您决定 Foundayo 是否适合您的最佳人选。

OG CON BS APR2026

OG CON BS 2026年4月

Foundayo

Foundayo

™

商标

is a trademark of Eli Lilly and Company.

是礼来公司的商标。

U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

美国ZEPBOUND适应症与安全概要（含警告）

Zepbound

泽普邦德

®

®

(ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

(ZEHP-bownd) 是一种处方注射药物，配合低热量饮食和增加体力活动，用于帮助成人：

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

肥胖症，或伴有体重相关医学问题的超重成人，以减轻多余体重并维持减重效果。

moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.

中重度阻塞性睡眠呼吸暂停（OSA）和肥胖，以改善其OSA。

Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any

Zepbound 含有替尔泊肽，不应与其他含替尔泊肽的产品或任何

GLP-1

GLP-1

receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

受体激动剂类药物。目前尚不清楚Zepbound在儿童中的使用是否安全有效。

Warnings -

警告 -

Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Zepbound 可能导致甲状腺肿瘤，包括甲状腺癌。请留意可能的症状，如颈部肿块或肿胀、声音嘶哑、吞咽困难或呼吸短促。如果出现任何上述症状，请告知您的医疗保健提供者。

Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).

如果您或您的家人曾患有称为髓样甲状腺癌（MTC）的甲状腺癌，请勿使用Zepbound。

Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

如果您患有2型多发性内分泌腺瘤病（MEN 2），请勿使用Zepbound。

Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.

如果您曾对替尔泊肽或 Zepbound 中的任何成分发生过严重过敏反应，请勿使用 Zepbound。

KwikPen

快笔

®

®

: Do not share your KwikPen with other people, even if the pen needle has been changed.

请勿与他人共用您的 KwikPen，即使已更换笔针。

You may give other people a serious infection or get a serious infection from them.

你可能会使他人感染严重的疾病，或者从他人那里感染严重的疾病。

Zepbound may cause serious side effects, including:

Zepbound 可能会引起严重的副作用，包括：

Severe stomach problems

严重的胃部问题

. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

. 已有报告指出，使用 Zepbound 的人群中会出现胃部问题，有时可能较为严重。如果您出现严重或持续不缓解的胃部问题，请告知您的医疗保健提供者。

Dehydration leading to kidney problems.

脱水导致肾脏问题。

Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

腹泻、恶心和呕吐可能导致体液流失（脱水），从而引发肾脏问题。务必充分饮水，以降低脱水风险。如果出现持续不退的恶心、呕吐或腹泻，请立即告知您的医疗保健提供者。

Gallbladder problems.

胆囊问题。

Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

部分使用Zepbound的患者曾出现胆囊问题。如果您出现胆囊问题的症状，包括上腹部（腹腔）疼痛、发热、皮肤或眼睛发黄（黄疸）或陶土色粪便，请立即告知您的医疗保健提供者。

Inflammation of the pancreas (pancreatitis).

胰腺炎症（胰腺炎）。

Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

如果您出现严重且持续不缓解的腹部（胃区）疼痛，无论是否伴有恶心或呕吐，请立即停用 Zepbound 并马上联系您的医疗保健提供者。您可能会感到腹痛放射至背部。

Serious allergic reactions.

严重过敏反应。

Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

如果您出现任何严重过敏反应的症状，包括面部、嘴唇、舌头或喉咙肿胀，呼吸或吞咽困难，严重皮疹或瘙痒，昏厥或感到头晕，或心跳极快，请立即停止使用 Zepbound 并寻求医疗帮助。

Low blood sugar (hypoglycemia).

低血糖（低血糖症）。

Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin.

如果您将 Zepbound 与可能导致低血糖的药物（如磺酰脲类药物或胰岛素）联合使用，您发生低血糖的风险可能会更高。

Signs and symptoms of low blood sugar

低血糖的体征和症状

may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

可能包括头晕或头昏、出汗、意识模糊或嗜睡、头痛、视力模糊、言语不清、颤抖、心跳加快、焦虑、易怒、情绪变化、饥饿感、虚弱或感到紧张不安。

Changes in vision in patients with type 2 diabetes.

2型糖尿病患者视力的变化。

Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

如果您在服用Zepbound期间出现视力变化，请告知您的医疗保健提供者。

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).

在手术或使用麻醉或深度镇静（深度睡眠状态）的其他操作过程中，食物或液体进入肺部。

Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Zepbound 可能会增加在手术或其他操作过程中食物进入肺部的风险。在安排手术或其他操作之前，请告知所有您的医疗保健提供者您正在使用 Zepbound。

Common side effects

常见副作用

The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss

Zepbound 最常见的副作用包括恶心、腹泻、呕吐、便秘、胃（腹部）疼痛、消化不良、注射部位反应、疲劳感、过敏反应、嗳气和脱发

,

，

and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

以及胃灼热。这些并非Zepbound所有可能的副作用。如有任何令您困扰或持续不退的副作用，请咨询您的医疗保健提供者。

Tell your doctor if you have any side effects.

如有任何副作用，请告知医生。

You can report side effects at 1-800-FDA-1088 or

您可以通过 1-800-FDA-1088 报告副作用，或

www.fda.gov/medwatch

www.fda.gov/medwatch

.

。

Before using Zepbound

使用 Zepbound 之前

Your healthcare provider should show you how to use Zepbound before you use it for the first time.

在首次使用 Zepbound 之前，您的医疗保健提供者应向您展示如何正确使用该药物。

Talk to your healthcare provider about low blood sugar and how to manage it. Tell your

与您的医疗保健提供者讨论低血糖问题及其管理方法。告知您的

healthcare provider if you are taking medicines to treat diabetes including an insulin or

如果您正在服用治疗糖尿病的药物，包括胰岛素，请联系医疗保健提供者

sulfonylurea.

磺酰脲类

If you take birth control pills by mouth, talk to your healthcare provider before you use

如果您口服避孕药，请在使用前咨询您的医疗保健提供者

Zepbound. Birth control pills may not work as well while using Zepbound.

Zepbound。在使用 Zepbound 期间，避孕药的效果可能会降低。

Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound.

在您开始使用Zepbound后的4周内，以及每次增加Zepbound剂量后的4周内，您的医疗保健提供者可能会建议您使用另一种类型的避孕方法。

Review these questions with your healthcare provider:

与您的医疗保健提供者一起回顾这些问题：

❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?

❑ 您是否有其他疾病，包括胰腺问题，或严重的胃部问题，例如胃排空延迟（胃轻瘫）或食物消化障碍？

❑ Do you take diabetes medicines, such as insulin or sulfonylureas?

❑ 您是否服用糖尿病药物，例如胰岛素或磺酰脲类药物？

❑ Do you have a history of diabetic retinopathy?

❑ 您是否有糖尿病视网膜病变病史？

❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?

❑ 您是否已安排进行需要使用麻醉或深度镇静（深睡状态）的手术或其他操作？

❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?

❑ 您是否正在服用其他处方药、非处方药、维生素或草本补充剂？

❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound..

❑ 您是否怀孕、计划怀孕、正在哺乳或计划哺乳？Zepbound 可能对您的胎儿造成伤害。如果您在使用 Zepbound 期间怀孕，请告知您的医疗保健提供者。Zepbound 可能进入您的母乳中。您应与医疗保健提供者讨论在使用 Zepbound 期间喂养宝宝的最佳方式。

Pregnancy Exposure Registry:

妊娠暴露登记处：

There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at .

有一个针对在怀孕期间使用过Zepbound的女性的妊娠暴露登记系统。该登记系统的目的是收集关于您和宝宝健康的信息。请与您的医疗保健提供者讨论如何参与此登记系统，或者您可以拨打1-844-524-0039或通过电子邮件联系。

[email protected]

[email protected]

or visit

或访问

https://pregnancyregistry.lilly.com/zepbound

https://pregnancyregistry.lilly.com/zepbound

.

。

How to take

如何服用

Read the Instructions for Use that come with Zepbound.

阅读随 Zepbound 附带的说明书。

Use Zepbound exactly as your healthcare provider says.

请严格遵照医疗保健提供者的指示使用 Zepbound。

Use Zepbound with a reduced-calorie diet and increased physical activity.

使用Zepbound时应配合低热量饮食和增加体力活动。

Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or

将 Zepbound 注射于腹部、大腿或上臂外侧的皮下组织。

have another person inject in the back of the upper arm.

让另一个人注射在上臂后侧。

Do not

不要

inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously).

将 ZEPBOUND 注射到肌肉（肌内注射）或静脉（静脉注射）中。

Use Zepbound 1 time each week, at any time of the day.

每周使用一次 Zepbound，一天中的任何时间均可。

Change (rotate) your injection site with each weekly injection.

每次每周注射时更换（轮换）注射部位。

Do not

不要

use the same site for each injection.

每次注射使用同一部位。

If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

如果您服用了过量的 Zepbound，请立即联系您的医疗保健提供者、拨打中毒帮助热线 1-800-222-1222，或前往最近的医院急诊室。

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Zepbound 已获批为 2.5 mg、5 mg、7.5 mg、10 mg、12.5 mg 和 15 mg 的注射剂。

Learn more

了解更多

Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to

Zepbound 是一种处方药。欲了解更多信息，请致电 1-800-LillyRx（1-800-545-5979）或访问

www.zepbound.lilly.com

www.zepbound.lilly.com

.

。

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it.

本摘要提供关于Zepbound的基本信息，但并未包含该药品的所有已知信息。每次配药时，请阅读随处方附带的说明资料。本信息不能替代与您的医疗保健提供者的沟通。请务必就Zepbound及其服用方法与您的医疗保健提供者进行咨询。

Your healthcare provider is the best person to help you decide if Zepbound is right for you..

您的医疗保健提供者是帮助您决定Zepbound是否适合您的最佳人选。

ZP CON BS 01SEP2026

ZP CON BS 2026年9月1日

Zepbound

泽邦德

®

®

, its delivery device base and KwikPen

、其给药装置底座及KwikPen

®

®

are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

是礼来公司及其子公司或关联公司拥有或许可的注册商标。

About Lilly

关于礼来

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases.

礼来是一家将科学转化为疗愈、以改善全球人民生活的医药公司。150年来，我们一直引领着改变生命的发现，如今我们的药物帮助了全球数千万人。凭借生物技术、化学和基因医学的力量，我们的科学家正迫切推进新发现，以应对一些全球最重大的健康挑战：重新定义糖尿病护理；治疗肥胖并遏制其最具破坏性的长期影响；推进对抗阿尔茨海默病的斗争；为一些最使人衰弱的免疫系统疾病提供解决方案；并将最难治疗的癌症转化为可管理的疾病。

With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit .

每向更健康的世界迈进一步，我们都由一个目标所激励：让数百万人的生活变得更美好。这包括开展反映世界多样性的创新临床试验，并致力于确保我们的药物可及且负担得起。欲了解更多信息，请访问。

Lilly.com

礼来公司官网

and

和

Lilly.com/news

Lilly.com/新闻

, or follow us on

，或在 上关注我们

Facebook

Facebook

,

，

Instagram

Instagram

, and

，和

LinkedIn

领英

. P-LLY

. P-LLY

Trademarks and Trade Names

商标和商号

All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the .

本新闻稿中提及的所有商标或商号均为本公司财产，或在涉及其他公司商标或商号的情况下，归其各自所有者所有。仅为方便起见，本新闻稿在提及商标和商号时未加标注。

®

®

and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. .

及™符号，但此类引用不应被解释为公司或（在适用范围内）其各自权利人不会依据适用法律充分主张其相关权利的任何指示。我们无意通过使用或展示其他公司的商标和商号来暗示与任何其他公司存在关系，或获得其认可或赞助。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo (orforglipron) as a potential treatment for adults with type 2 diabetes, potential efficacy and tolerability of Foundayo, and the timeline for future readouts, presentations, and other milestones relating to Foundayo and its clinical trials and reflects Lilly's current beliefs and expectations.

本新闻稿包含有关Foundayo（orforglipron）作为成人2型糖尿病潜在疗法的、关于Foundayo的潜在疗效和耐受性的，以及关于与Foundayo及其临床试验相关的未来数据读出、演示和其他里程碑时间表的“前瞻性陈述”（该术语定义于1995年《私人证券诉讼改革法》），并反映了礼来公司当前的信念和预期。

However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with expectations or study results to date, that Foundayo will prove to be a safe and effective treatment for type 2 diabetes, that Foundayo will receive additional regulatory approvals, or that Lilly will execute its strategy as expected.

然而，与任何医药产品一样，在药物的研发和商业化过程中存在重大风险和不确定性。其中包括：无法保证计划中或正在进行的研究会按计划完成；无法保证未来的研究结果会与预期或迄今的研究结果一致；无法保证Foundayo将被证明是治疗2型糖尿病的安全有效药物；无法保证Foundayo会获得额外的监管批准；也无法保证礼来公司会按预期执行其战略。

For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. .

有关可能导致实际结果与礼来公司预期存在差异的上述及其他风险和不确定性的进一步讨论，请参阅礼来公司向美国证券交易委员会提交的10-K表和10-Q表文件。除非法律另有要求，礼来公司不承担更新前瞻性陈述以反映本新闻稿发布日后发生的事件的义务。

Refer to:

请参考：

Niki Biro;

尼基·比罗；

[email protected]

[email protected]

(Media)

（媒体）

Michael Czapar;

迈克尔·查帕尔；

[email protected]

[email protected]

(Investors)

（投资者）

SOURCE Eli Lilly and Company

来源：礼来公司

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示